Affordable Access

Publisher Website

Mutualisation des outils de qualité pour les cellules CAR-T : recommandations de la Société francophone de greffe de moelle et thérapie cellulaire (SFGM-TC)

  • Duléry, Rémy
  • Lacassagne, Marie-Noëlle
  • Giraud, Christine
  • Ader, Virginie
  • Beaumont, Jean-Louis
  • Carnoy, Sylvie
  • Carpentier, Alexandre
  • Fegueux, Nathalie
  • Gibault-Joffe, Cécile
  • Guerout-Verite, Marie-Agnès
  • Huynh, Thi Ngoc Phuong
  • Lewalle, Philippe
  • Perrin, Agnès
  • Plaza-Milhe, Sophie
  • Bonnin, Agnès
  • Yakoub-Agha, Ibrahim
  • Contentin, Nathalie
Publication Date
Dec 31, 2020
DOI: 10.1016/j.bulcan.2020.10.001
PMID: 33187683
OAI: oai:HAL:hal-03493426v1
External links


CAR T-cells are anti-cancer immunocellular therapy drugs that involve reprogramming the patient's T-cells using a transgene encoding a chimeric antigen receptor (CAR). Although CAR T-cells are cellular therapies, the organization for manufacturing and delivering these medicinal products is in many ways different from the one for hematopoietic cell grafts or donor lymphocyte infusions. The implementation of this innovative therapy is recent and requires close coordination between clinical teams, the therapeutic apheresis unit, the cell therapy unit, the pharmaceutical laboratory, and pharmacy. Apart from the regulatory texts, which are regularly modified, and the specific requirements of each pharmaceutical laboratory, there is currently no guide to help the centers initiating their activity and there is no specific indicator to assess the quality of the CAR T-cell activity in each center. The purpose of the current harmonization workshop is to clarify the regulatory prerequisites warranted for a center to have a CAR T-cell activity and to propose recommendations for implementing quality tools, in particular indicators, and allowing their sharing.

Report this publication


Seen <100 times